We are live on ! Find out more
BRA

Bender Robert & Associates Portfolio holdings

AUM $481M
1-Year Est. Return 35.73%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+35.73%
3 Year Est. Return
+116.09%
5 Year Est. Return
+167.64%
10 Year Est. Return
+1,066.43%
AUM
$414M
AUM Growth
-$56.6M
Cap. Flow
-$78.1M
Cap. Flow %
-18.85%
Top 10 Hldgs %
73.42%
Holding
47
New
8
Increased
13
Reduced
22
Closed
1

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$415K
2
EOLS icon
Evolus
EOLS
+$353K
3
SMMT icon
Summit Therapeutics
SMMT
+$223K
4
PAYX icon
Paychex
PAYX
+$207K
5
TROW icon
T. Rowe Price
TROW
+$205K

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$33.8M
2
NVDA icon
NVIDIA
NVDA
+$13M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.12M
4
LULU icon
lululemon athletica
LULU
+$5.6M
5
META icon
Meta Platforms (Facebook)
META
+$4.58M

Sector Composition

Rank Sector Weight
1 Technology 44.5%
2 Consumer Discretionary 22.13%
3 Healthcare 17.68%
4 Communication Services 11.92%
5 Financials 2.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COST icon
26
Costco
COST
$407B
$1.36M 0.33%
1,482
+54
+4% +$50.1K
GILD icon
27
Gilead Sciences
GILD
$181B
$957K 0.23%
10,363
-971
-9% -$87.4K
AZN icon
28
AstraZeneca
AZN
$254B
$799K 0.19%
6,101
-840
-12% -$118K
ABBV icon
29
AbbVie
ABBV
$462B
$764K 0.18%
4,297
-32
-0.7% -$5.88K
JPM icon
30
JPMorgan Chase
JPM
$930B
$660K 0.16%
2,754
-94
-3% -$21.9K
ABT icon
31
Abbott
ABT
$178B
$638K 0.15%
5,638
-133
-2% -$15.4K
JNJ icon
32
Johnson & Johnson
JNJ
$645B
$538K 0.13%
3,719
+180
+5% +$27.9K
MRK icon
33
Merck
MRK
$358B
$496K 0.12%
4,982
– –
DE icon
34
Deere & Co
DE
$183B
$429K 0.1%
1,012
-3
-0.3% -$1.26K
CAT icon
35
Caterpillar
CAT
$362B
$393K 0.1%
1,084
-5
-0.5% -$1.94K
URGN icon
36
UroGen Pharma
URGN
$2.1B
$370K 0.09%
+34,701
New +$415K
ORCL icon
37
Oracle
ORCL
$415B
$325K 0.08%
1,949
– –
V icon
38
Visa
V
$702B
$319K 0.08%
1,009
+115
+13% +$34.6K
NUE icon
39
Nucor
NUE
$57.6B
$283K 0.07%
2,425
– –
EOLS icon
40
Evolus
EOLS
$530M
$277K 0.07%
+25,070
New +$353K
SMMT icon
41
Summit Therapeutics
SMMT
$14.8B
$205K 0.05%
+11,496
New +$223K
PAYX icon
42
Paychex
PAYX
$42.1B
$204K 0.05%
+1,455
New +$207K
PLSE icon
43
Pulse Biosciences
PLSE
$3.91B
$202K 0.05%
+11,590
New +$204K
TROW icon
44
T. Rowe Price
TROW
$22.5B
$200K 0.05%
+1,770
New +$205K
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.1B
$178K 0.04%
+23,710
New +$180K
CMRX
46
DELISTED
Chimerix, Inc.
CMRX
$36.9K 0.01%
+10,609
New +$15K
AEP icon
47
American Electric Power
AEP
$66.8B
– –
-2,050
Closed -$210K
1
2

Similar funds

MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $481M AUM 22.61% 1-Year Est. Return
SA
Stewardship Advisors Mount Joy, Pennsylvania $481M AUM 18.41% 1-Year Est. Return
NC
NovaPoint Capital Atlanta, Georgia $481M AUM 32.01% 1-Year Est. Return
HWMG
Hurlow Wealth Management Group Bloomington, Indiana $481M AUM 20.5% 1-Year Est. Return
MAV
Mason & Associates (Virginia) Newport News, Virginia $481M AUM 12.85% 1-Year Est. Return
OMIC
Old Mission Investment Co Traverse City, Michigan $481M AUM
SCA
Sage Capital Advisors Sioux Falls, South Dakota $482M AUM 34.73% 1-Year Est. Return

Bender Robert & Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Bender Robert & Associates held 47 positions worth $414M, down 12% from $471M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Bender Robert & Associates withdrew a net $78.1M in Q4 2024, closing 1 position and reducing 22 holdings. Its most notable exit was American Electric Power, an estimated $210K position sold in full.

By sector, the portfolio is most concentrated in Technology at 44% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Bender Robert & Associates opened a new position in UroGen Pharma worth $370K.

  • Bender Robert & Associates's largest Q4 2024 buy was UroGen Pharma: 34,701 shares worth $370K.
  • Bender Robert & Associates added most to Eli Lilly in Q4 2024, an estimated $192K increase.
  • Bender Robert & Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $33.8M.
  • Bender Robert & Associates fully exited American Electric Power in Q4 2024, selling an estimated $210K.
  • Bender Robert & Associates's ten largest holdings make up 73% of its $414M portfolio in Q4 2024.
  • Bender Robert & Associates opened 8 new positions and closed 1 in Q4 2024.
  • Bender Robert & Associates's portfolio value fell 12% quarter-over-quarter to $414M.

Based on Bender Robert & Associates's 13F filing for Q4 2024, filed 7 Feb 2025.